NCT00756067View on ClinicalTrials.gov

Evaluation of Pneumococcal Vaccine Formulations in Elderly

PHASE1CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

September 19, 2008

Primary Completion Date

May 28, 2009

Study Completion Date

May 28, 2009

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK2189241A

Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

BIOLOGICAL

Pneumo 23™

One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.

Trial Locations (3)

SE-205 02

GSK Investigational Site, Malmo

SE-701 85

GSK Investigational Site, Örebro

SE-751 85

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY